User contributions for Lazy

31 March 2024

• 13:2713:27, 31 March 2024 diff hist +2,921‎ N Wilms Tumor 1 (WT1) Peptide Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi..."
• 13:2313:23, 31 March 2024 diff hist +3,809‎ N Rindopepimut (CDX-110) ‎ Created page with "{{TreatmentInfo |drug_name=Rindopepimut (CDX-110) |FDA_approval=Not FDA-approved; received Breakthrough Therapy designation for glioblastoma in Feb 2015 |used_for=EGFRvIII-positive Glioblastoma Multiforme (GBM) in newly diagnosed and recurrent cases |clinical_trial_phase=Phase III for newly diagnosed GBM was discontinued; Phase II for recurrent GBM showed promising results |common_side_effects=Transient, low-grade local reactions; overall well-tolerated |OS_without=Media..."
• 13:1913:19, 31 March 2024 diff hist +4,449‎ N Anti-CMV Dendritic Cell Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Anti-CMV Dendritic Cell Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Not detailed; dendritic cell vaccines are generally well-tolerated with mild side effects. |OS_without=Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM. |OS_with=Varied; one study showed medi..."
• 13:1413:14, 31 March 2024 diff hist +2,361‎ N SL-701 ‎ Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv..."
• 13:1013:10, 31 March 2024 diff hist +7,097‎ N ICT-107 ‎ Created page with "{{TreatmentInfo |drug_name=ICT-107 (Tumor-associated Antigen Vaccine) |FDA_approval=Still in clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase III |common_side_effects=Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported. |OS_without=Median overall survival for GBM typically rang..."
• 13:0613:06, 31 March 2024 diff hist +3,218‎ N Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine ‎ Created page with "{{TreatmentInfo |drug_name=Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Recurrent heavily pretreated glioblastoma multiforme (GBM) and newly diagnosed GBM |clinical_trial_phase=Phase II |common_side_effects=Not explicitly detailed; similar immunotherapy treatments often include flu-like symptoms, injection site reactions, fatigue |OS_without=Historical controls suggest a median survival t..." current
• 13:0113:01, 31 March 2024 diff hist +6,839‎ N Dendritic Cell Vaccine (DCVax-L) ‎ Created page with "{{TreatmentInfo |drug_name=Dendritic Cell Vaccine (DCVax-L) |FDA_approval=Under investigation; not yet FDA-approved |used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent |clinical_trial_phase=Phase 3 |common_side_effects=Intracranial edema, nausea, lymph node infection (rare and manageable) |OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence |OS_with=Median overall survival of 19.3 months..." current
• 12:5812:58, 31 March 2024 diff hist −14‎ BCNU (Carmustine) and Gliadel (Carmustine Wafers) ‎No edit summary current
• 12:5512:55, 31 March 2024 diff hist +2,150‎ Main Page ‎No edit summary
• 11:2611:26, 31 March 2024 diff hist −30‎ Template:TreatmentInfo ‎No edit summary
• 11:2511:25, 31 March 2024 diff hist +25‎ Template:TreatmentInfo ‎No edit summary
• 11:2411:24, 31 March 2024 diff hist −12‎ Template:TreatmentInfo ‎No edit summary
• 11:2311:23, 31 March 2024 diff hist +52‎ Template:TreatmentInfo ‎No edit summary
• 10:0310:03, 31 March 2024 diff hist +18‎ N Property:Has Toxicity Explanation ‎ Created page with "Has type::Text" current
• 10:0010:00, 31 March 2024 diff hist +291‎ Category:Other Chemotherapy and Cancer Drugs ‎No edit summary current
• 09:5909:59, 31 March 2024 diff hist 0‎ Category:Antibody-Drug Conjugates and other protein-drug conjugates ‎ →‎List of Treatments current
• 09:5709:57, 31 March 2024 diff hist +146‎ Category:Antibody-Drug Conjugates and other protein-drug conjugates ‎No edit summary
• 09:5509:55, 31 March 2024 diff hist +14‎ Category:Antibody-Drug Conjugates and other protein-drug conjugates ‎No edit summary
• 09:5409:54, 31 March 2024 diff hist +14‎ Category:Nutraceuticals ‎No edit summary current
• 09:5409:54, 31 March 2024 diff hist +14‎ Category:Hormones ‎No edit summary current
• 09:5409:54, 31 March 2024 diff hist +14‎ Category:Repurposed Drugs ‎No edit summary current
• 09:5109:51, 31 March 2024 diff hist +16‎ Template:TreatmentInfo ‎No edit summary
• 09:4809:48, 31 March 2024 diff hist +15‎ Main Page ‎No edit summary
• 06:2406:24, 31 March 2024 diff hist −31‎ Main Page ‎No edit summary
• 06:2306:23, 31 March 2024 diff hist +920‎ Main Page ‎No edit summary

30 March 2024

• 21:0121:01, 30 March 2024 diff hist −1‎ Main Page ‎No edit summary
• 20:4920:49, 30 March 2024 diff hist +1,903‎ N CPT-11 (Irinotecan) ‎ Created page with "{{TreatmentInfo |drug_name=CPT-11 (Irinotecan) |FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma |used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas |clinical_trial_phase=Phase I/II trials in combination with other therapies |common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens |OS_without=Not directly specified; histori..." current
• 20:4720:47, 30 March 2024 diff hist +1,948‎ N Carboplatin ‎ Created page with "{{TreatmentInfo |drug_name=Carboplatin |FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma |clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents |common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation |OS_with..." current
• 20:4520:45, 30 March 2024 diff hist +2,165‎ N Fotemustine ‎ Created page with "{{TreatmentInfo |drug_name=Fotemustine |FDA_approval=Available in Europe, not FDA-approved in the United States for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) after the standard Stupp protocol treatment |clinical_trial_phase=Varied, with multiple studies evaluating efficacy and optimal scheduling |common_side_effects=Not specified, typical of nitrosoureas may include myelosuppression, nausea, and liver enzyme elevation |OS_without=Not specified |OS_with=Not sp..." current
• 20:4220:42, 30 March 2024 diff hist +2,138‎ N BCNU (Carmustine) ‎ Created page with "{{TreatmentInfo |drug_name=BCNU (Carmustine) |FDA_approval=Yes, approved for treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas |used_for=Recurrent Glioblastoma Multiforme (GBM) after radiation treatment |clinical_trial_phase=Various, given its long history of use |common_side_effects=Hepatic and pulmonary toxicity, myelosuppression |OS_without=Not specified in the provided context |OS_with=Not specified in the provided context |P..." current
• 20:3920:39, 30 March 2024 diff hist +1,923‎ N VAL-083 (Dianhydrogalactitol) ‎ Created page with "{{TreatmentInfo |drug_name=VAL-083 (Dianhydrogalactitol) |FDA_approval=Approved in China for CML and lung cancer; not yet approved outside of China for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) with unmethylated MGMT promoter |clinical_trial_phase=Phase 2 (ongoing evaluation in GBM AGILE for various GBM subtypes) |common_side_effects=Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083 |..." current
• 10:0810:08, 30 March 2024 diff hist 0‎ BCNU (Carmustine) and Gliadel (Carmustine Wafers) ‎No edit summary
• 09:2009:20, 30 March 2024 diff hist +24‎ N Template:CustomTextDisplay ‎ Created page with "{{{Has original text|}}}" current
• 09:2009:20, 30 March 2024 diff hist +36‎ Main Page ‎ →‎Optune (formerly NovoTTF-100A) by Novocure
• 09:1609:16, 30 March 2024 diff hist +23‎ Main Page ‎ →‎Optune (formerly NovoTTF-100A) by Novocure
• 09:1509:15, 30 March 2024 diff hist +5‎ Main Page ‎ →‎Available Treatments
• 09:1309:13, 30 March 2024 diff hist +23‎ Template:TreatmentInfo ‎No edit summary
• 09:1109:11, 30 March 2024 diff hist +80‎ Main Page ‎ →‎Optune (formerly NovoTTF-100A) by Novocure
• 09:0909:09, 30 March 2024 diff hist +1‎ Template:TreatmentInfo ‎No edit summary
• 09:0809:08, 30 March 2024 diff hist +105‎ Template:TreatmentInfo ‎No edit summary
• 09:0709:07, 30 March 2024 diff hist +154‎ Next-Generation CAR T-Cell Therapy for GBM ‎No edit summary current
• 09:0409:04, 30 March 2024 diff hist +2,325‎ N Next-Generation CAR T-Cell Therapy for GBM ‎ Created page with "{{TreatmentInfo |drug_name=Next-Generation CAR T-Cell Therapy for GBM |FDA_approval=In trial phase for GBM; FDA-approved for other cancers |used_for=Recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase 1 (INCIPIENT trial among others) |common_side_effects=Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity |OS_without=Median survival for recurrent GBM typically less than one year |OS_with=Not fully established; dr..." Tag: Visual edit: Switched
• 08:3508:35, 30 March 2024 diff hist +51‎ Main Page ‎ →‎Vaccines Tag: Visual edit
• 08:3408:34, 30 March 2024 diff hist +106‎ Main Page ‎ →‎Promising new Treatments Tag: Visual edit
• 08:3008:30, 30 March 2024 diff hist −1‎ Main Page ‎ →‎Other Chemotherapy and Cancer Drugs Tag: Visual edit

29 March 2024

• 23:4023:40, 29 March 2024 diff hist +1,820‎ EGFR inhibitors: Iressa, Tarceva, and Erbitux (gefitinib, erlotinib, and ‎No edit summary current
• 23:3523:35, 29 March 2024 diff hist 0‎ Main Page ‎ →‎Other Chemotherapy and Cancer Drugs
• 23:3423:34, 29 March 2024 diff hist +48‎ Main Page ‎ →‎Other Chemotherapy and Cancer Drugs
• 23:3323:33, 29 March 2024 diff hist +16,888‎ Main Page ‎ →‎Other Chemotherapy and Cancer Drugs
• 23:2923:29, 29 March 2024 diff hist −64‎ Radiation via Monoclonal Antibodies ‎No edit summary current